Full Title
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma (SN2426) (CIRB)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Lara Dunn’s office at 646-608-3787.
Protocol
26-130
Phase
Phase II (phase 2)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07042295